SLCO1B3 and prostate carcinoma: Even if afatinib has not been described as a good substrate of this transporter, we cannot exclude that PXR-mediated intracellular accumulation of afatinib may also be due to the induction of other influx pumps that are expressed in prostate cancer such as SLCO1B3 [47].